CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-11-20 slientwo

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤研究
经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。

160 0

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2020-10-27 Lord Megatron

要不要版面费，这期刊

181 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2021-07-21 1582019d51m

请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢

101 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-06-13 1663238685_12506575

CR内审和外审都是Under Review吗

113 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-10-19 duanbiao127

为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2020-07-24 silent111

审稿速度:2.0 | 投稿命中率:25.0
经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。

1 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-04-15 tckkhf2006

审稿速度:2.0 | 投稿命中率:5.0
经验分享：1周多点拒稿，还是很难中的！

85 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2021-05-29 张晓梅-Xiaomei Zhang

期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。
大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏

194 19

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-10-02 鸡爪

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？

53 0

[GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894681, encodeId=3b5a89468193, content=要不要版面费，这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=181, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Tue Oct 27 01:02:14 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001382, encodeId=1e39100138251, content=请问状态变成under review指送外审了吗？但是没有收到送审的邮件通知呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ddd92153968, createdName=1582019d51m, createdTime=Wed Jul 21 13:09:03 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226137, encodeId=de88122613ec4, content=CR内审和外审都是Under Review吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b48f5153036, createdName=1663238685_12506575, createdTime=Mon Jun 13 11:29:54 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804355, encodeId=335180435555, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：大家好，问个问题：投稿CR后，会显示一个方法上的Score，这个打分对评审文章有用么？大家都打了多少分？有打4分的么？谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:33:18 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211325, encodeId=b9491211325ab, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：1周多点拒稿，还是很难中的！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11e5109668, createdName=tckkhf2006, createdTime=Fri Apr 15 06:21:02 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969493, encodeId=7d30969493ae, content=期刊质量高，认可度很高。有一篇这个去申国自然青年基本稳中，面上也大概率能过函评。和其他8、9分的期刊像oncogene/cancer letter/Theranostics完全不是一个档次的。 大家还是争取发这种高质量期刊申基金才有用，现在内卷严重，评委不是吃素的，看到发的都是oncogene/cancer letter/Theranostics这种期刊基本没戏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Sat May 29 18:16:55 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089093, encodeId=3b14208909313, content=偏重的研究方向：肿瘤 经验分享：各位大神，CR送外审不会发邮件通知么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fabe6455220, createdName=ms5000001982894673, createdTime=Mon Sep 19 20:06:42 CST 2022, time=2022-09-19, status=1, ipAttribution=)]

2022-09-19 ms5000001982894673

偏重的研究方向：肿瘤
经验分享：各位大神，CR送外审不会发邮件通知么？

59 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务